ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2121

A Multi-Biomarker Disease Activity (VECTRA™ DA Algorithm) Score Reflects Clinical Disease Activity and Structural Changes in Rheumatoid Arthritis Patients Treated with Tocilizumab

Yoshiya Tanaka1, Kentaro Hanami2, Hisashi Tasaka1, Shunsuke Fukuyo1, Douglas J. Haney3, Nadine Defranoux3, Rebecca Bolce3, Guy Cavet3, David Chernoff3, Kunihiro Yamaoka1, Kazuyoshi Saito1 and Shintaro Hirata1, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2The First Department of Internal Medicinei, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 3Crescendo Bioscience Inc., South San Francisco, CA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Activity score, Biomarkers, rheumatoid arthritis (RA) and tocilizumab

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Rheumatoid Arthritis - Clinical Aspects III: Infections/Risk Factors for Incident Rheumatoid Arthritis/Metrology/Classification/Biomarkers/Predictors of Rheumatolid Arthritis Activity & Severity

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The multi-biomarker disease activity (MBDA) score assessed with 0.2 mL serum has been reported as a novel composite disease activity index for patients with rheumatoid arthritis (RA). We reported the correlation of MBDA score with conventional composite measures such as DAS28 in patients with RA. However, the estimation of the MBDA score in RA patients treated with anti-IL-6 receptor antibody tocilizumab (TCZ) has not been investigated. Purpose of this study is to clarify if the MBDA score could reflect disease activity and track therapeutic effect including clinical and radiographic outcomes in RA patients treated with TCZ.

Methods:

Fifty two RA patients who treated with TCZ were enrolled. The MBDA algorithm combines 12 serum biomarkers (VCAM-1, EGF, VEGF-A, IL-6, TNF-RI, MMP-1, MMP-3, YKL-40, Leptin, Resistin, CRP, SAA) into a single score from 1-100 according the Vectra™ DA algorithm. MBDA disease activity categories were defined as high (HDA>44), moderate (MDA>29≤44), low (LDA<25≤29) and remission (REM≤25). Radiographic changes were assessed by the modified total Sharp score (mTSS). For statistic analysis, Spearman's rank correlation coefficients and Pearson's chi-square test were used. All p-values are two sided and <0.05 were considered significant.

Results:

At baseline (BL), patients had median age of 57±18, disease duration of 12.4±11.2 years, DAS28 of 5.6±1.3, CDAI of 22.1±12.2, HAQ-DI of 1.4±0.9 and mTSS of 106±112. MTX was used in 86.5% and positivity of RF was 78.8%. MBDA score at BL was 57.7±19.2 and were correlated well with DAS28 and CDAI (ρ=0.63 and 0.57, respectively, p<0.0001). TCZ improved MBDA score from 57.7 to 43.7 and 42.5 at W24 and W52, respectively, DAS28 from 5.6 to 2.5 and 2.9, CDAI from 22.2 to 6.4 and 5.6, at BL, W24 and W52, respectively. Changes of MBDA from BL to 52W by TCZ were significantly correlated with those of DAS28 (r=0.471, p<0.001) and CDAI (r=0.373, p<0.01). MBDA-REM ratio at W52 was significantly correlated with DAS28-REM ratio (AUROC=0.643) and CDAI-REM ratio (0.768). Yearly progression of mTSS (ΔmTSS) was improved from 12.3±14.9 to 0.5±2.5 by TCZ and 77% achieved ΔmTSS<0. Interestingly, all patients who achieved MBDA-LDA (8), MBDA-REM (3) or Boolean-REM (5) at W24 showed ΔmTSS<0.5, whereas some of DAS28-REM and CDAI-REM did ΔmTSS>0.5. Patients who achieved MBDA-REM or Boolean-REM at W24 revealed higher likelihood ratio for achieving both radiographic and functional REM at W52 than those who DAS28-REM and CDAI-REM. 

Conclusion:

This is the first report of the MBDA estimated in RA patients treated with TCZ. TCZ efficiently improved MBDA score and BL and changes of MBDA were correlated with those of conventional composite measures. Although additional data are needed to assess the relationship between MBDA and radiographic and functional remission, The MBDA score reflects disease activity and tracks therapeutic effects and MBDA-REM might be preferable to DAS28-REM for predicting good outcome in both radiographic damage and physical function in RA patients treated with TCZ.


Disclosure:

Y. Tanaka,

Mitsubishi-Tanabe Pharma Corporation, Abbott Japan Co., Ltd., Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Santen Pharmaceutical Co., Ltd., Pfizer Japan Inc., Astellas Pharma Inc., Daiichi-Sankyo Co., Ltd., GlaxoSmithKlin,

8,

Bristol-Myers Squibb, MSD K.K., Chugai Pharmaceutical Co., Ltd., Mitsubishi-Tanabe Pharma Corporation, Astellas Pharma Inc., Abbott Japan Co., Ltd., Eisai Co., Ltd. and Janssen Pharmaceutical K.K,

2;

K. Hanami,
None;

H. Tasaka,

Chugai Pharmaceutical Co. Ltd.,

3;

S. Fukuyo,
None;

D. J. Haney,

Crescendo Bioscience Inc.,

3;

N. Defranoux,

Crescendo Bioscience Inc.,

3;

R. Bolce,

Crescendo Bioscience Inc.,

3;

G. Cavet,

Crescendo Bioscience Inc.,

3;

D. Chernoff,

Crescendo Bioscience Inc.,

3;

K. Yamaoka,
None;

K. Saito,
None;

S. Hirata,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-multi-biomarker-disease-activity-vectra-da-algorithm-score-reflects-clinical-disease-activity-and-structural-changes-in-rheumatoid-arthritis-patients-treated-with-tocilizumab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.